Malta - English - Medicines Authority

gambro lundia ab - calcium chloride, dihydrate, potassium chloride, glucose anhydrous, lactic acid, magnesium chloride, hexahydrate, sodium chloride, sodium hydrogen, carbonate - solution for haemofiltration - calcium chloride dihydrate 0.257 millimole(s)/litre ; potassium chloride 0.298 millimole(s)/litre ; glucose anhydrous 1.1 millimole(s)/litre ; lactic acid 0.27 millimole(s)/litre ; magnesium chloride hexahydrate 0.102 millimole(s)/litre ; sodium chloride 6.128 millimole(s)/litre ; sodium hydrogen carbonate 2.936 millimole(s)/litre - blood substitutes and perfusion solutions

Ireland - English - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag. - glucose monohydrate - solution for infusion - 5 grams/100 millilitres - i.v. solutions - cats, cattle, dogs, goats, horses, pigs, sheep - electrolytes

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - calcium chloride dihydrate,glucose monohydrate,magnesium chloride hexahydrate,potassium chloride,sodium bicarbonate,sodium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - calcium chloride dihydrate,glucose monohydrate,magnesium chloride hexahydrate,potassium chloride,sodium bicarbonate,sodium chloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius medical care australia pty ltd - calcium chloride dihydrate,glucose monohydrate,magnesium chloride hexahydrate,potassium chloride,sodium bicarbonate,sodium chloride -

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid, unspecified form (unii: 33x04xa5at) (lactic acid, unspecified form - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - unii:lyr4m0nh37, bicarbonate ion - unii:hn1zra3q20) - calcium chloride 0.184 g in 1 l - prismasol and phoxillum solutions are indicated in pediatric and adult patients for use as a replacement solution in continuous renal replacement therapy (crrt) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. they may also be used in case of drug poisoning when crrt is used to remove dialyzable substances. phoxillum and prismasol replacement solutions are contraindicated in patients with known hypersensitivities to these products. prismasol and phoxillum are pharmacologically inactive solutions. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with prismasol and phoxillum solutions. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. maintenance of normal acid-base balance is important for fetal well-being. the components of prismasol and phoxillum solutions are excreted in human milk. appropriate administration of prismasol and phoxillum solutions with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established based on published clinical data of crrt replacement solutions with compositions similar to prismasol and phoxillum used in adults and two hemofiltration studies in pediatric patients, including a study of newborns to 17 years old. the experience with prismasol and phoxillum solutions in geriatric patients has not identified novel concerns.

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - atorvastatin calcium propylene glycol solvate (unii: yrz789owmi) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 20 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: in patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calciu

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - atorvastatin calcium (unii: 48a5m73z4q) (atorvastatin - unii:a0jwa85v8f) - atorvastatin 10 mg - therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. in patients with chd or multiple risk factors for chd, atorvastatin calcium tablets can be started simultaneously with diet. in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low hdl-c, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to:  - reduce the risk of myocardial infarction     - reduce the risk of stroke     - reduce the risk for revascularization procedures and angina in patients with type 2 diabetes, and without clinically evident coronary heart dise

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - dextrose monohydrate 5 g in 100 ml - lactated ringer’s and 5% dextrose injection, usp is indicated as a source of water, electrolytes and calories or as an alkalinizing agent. lactated ringer’s and 5% dextrose injection, usp is contraindicated in: patients with a known hypersensitivity to sodium lactate (see warnings ).

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); atorvastatin calcium trihydrate, quantity: 86.8 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: calcium carbonate; pregelatinised maize starch; croscarmellose sodium; polysorbate 80; hyprolose; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; titanium dioxide; indigo carmine; purified talc; polyvinyl alcohol; macrogol 3000 - caduet (amlodipine and atorvastatin) is indicated for patients in whom treatment with amlodipine and atorvastatin is appropriate at the doses presented. the indications for amlodipine are: 1. hypertension: amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor. 2. angina: amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs. the indications for atorvastatin are: 1. atorvastatin is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, and alcoholism) should be identified and treated. 2. atorvastatin is indicated in hypertensive patients with multiple risk factors for coronary heart disease (chd) which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see clinical trials, prevention of cardiovascular disease) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.